Yap, Timothy A. http://orcid.org/0000-0002-2154-3309
Daver, Naval http://orcid.org/0000-0001-7103-373X
Mahendra, Mikhila http://orcid.org/0000-0001-6670-6792
Zhang, Jixiang http://orcid.org/0000-0002-1641-8650
Kamiya-Matsuoka, Carlos
Meric-Bernstam, Funda http://orcid.org/0000-0001-6816-6072
Kantarjian, Hagop M. http://orcid.org/0000-0002-1908-3307
Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Collins, Meghan E. http://orcid.org/0000-0002-6201-9298
Francesco, Maria Emilia Di
Dumbrava, Ecaterina E.
Fu, Siqing http://orcid.org/0000-0002-1933-0419
Gao, Sisi
Gay, Jason P.
Gera, Sonal
Han, Jing
Hong, David S. http://orcid.org/0000-0001-8721-1609
Jabbour, Elias J.
Ju, Zhenlin
Karp, Daniel D.
Lodi, Alessia
Molina, Jennifer R.
Baran, Natalia http://orcid.org/0000-0003-0618-4798
Naing, Aung http://orcid.org/0000-0002-4803-8513
Ohanian, Maro
Pant, Shubham
Pemmaraju, Naveen
Bose, Prithviraj http://orcid.org/0000-0002-4343-5712
Piha-Paul, Sarina A.
Rodon, Jordi
Salguero, Carolina
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Singh, Anand K.
Subbiah, Vivek http://orcid.org/0000-0002-6064-6837
Tsimberidou, Apostolia M.
Xu, Quanyun A.
Yilmaz, Musa http://orcid.org/0000-0002-4498-4895
Zhang, Qi http://orcid.org/0000-0002-7918-8952
Li, Yuan
Bristow, Christopher A.
Bhattacharjee, Meenakshi B.
Tiziani, Stefano
Heffernan, Timothy P. http://orcid.org/0000-0002-3166-8922
Vellano, Christopher P.
Jones, Philip
Heijnen, Cobi J.
Kavelaars, Annemieke
Marszalek, Joseph R. http://orcid.org/0000-0003-2320-3209
Konopleva, Marina http://orcid.org/0000-0002-9347-2212
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA100632, CA206210, CA016672)
U.S. Department of Health & Human Services | NIH | Center for Information Technology (1UL1TR003167, CA227064, 1UL1TR003167, CA227064, CA227064)
Cancer Prevention and Research Institute of Texas (RP120348, RP170002)
The Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Grant, the Leukemia & Lymphoma Society through its Therapy Acceleration Program (TAP), and the MD Anderson Moon Shots program.
Article History
Received: 30 March 2022
Accepted: 21 October 2022
First Online: 19 January 2023
Competing interests
: T.A.Y. is the Medical Director of the Institute for Applied Cancer Science (M.D Anderson Cancer Center), which has a commercial interest in DDR and other inhibitors (no. IACS30380/ART0380 was licensed to Artios). T.A.Y.’s research has been supported by Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, Vivace and Zenith; he has consulted for AbbVie, AstraZeneca, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Athena, Atrin, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, Boxer, Bristol-Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Clovis, Cybrexa, Diffusion, EMD Serono, F-Star, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Idience, Ignyta, I-Mab, ImmuneSensor, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Natera, Nexys, Novocure, OHSU, OncoSec, Ono Pharma, Pegascy, PER, Pfizer, Piper-Sandler, Prolynx, Repare, resTORbio, Roche, Schrodinger, Theragnostics, Varian, Versant, Vibliome, Xinthera, Zai Labs and ZielBio; he is a stockholder in Seagen. N.D. has received research funding from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi Sankyo, Abbvie, Hanmi, Trovagene, FATE therapeutics, Amgen, Novimmune, Glycomimetics, Trillium and ImmunoGen and has served in a consulting or advisory role for Daiichi Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck labs and Agios. M.K. has received research funding from AbbVie, Genentech, F. Hoffman La Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, AstraZeneca, Rafael Pharmaceutical, Sanofi and Forty-Seven and has served in a consulting or advisory role for AbbVie, Genentech, F. Hoffman La Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji and Janssen. N.P. serves on the Board of Directors for the following: Dan’s House of Hope; Consulting: AbbVie, Aptitude Health, Astellas Pharma US, Inc., Blueprint Medicines, Bristol-Myers Squibb, Celgene Corp, Cimeio Therapeutics AG, ClearView Healthcare Partners, CTI BioPharma, Dava Oncology, Immunogen, Incyte, Intellisphere, LLC., Novartis AG, Novartis Pharmaceuticals Corp, OncLive (Owned by Intellisphere, LLC), Patient Power, PharmaEssentia, Protagonist Therapeutics, Sanofi-aventis, Stemline Therapeutics, Inc. and Total CME; financial relationships (for example, Stock, Royalty, Gift, Employment or Business Ownership): Karger Publishers; Scientific/Advisory Committee Member: Cancer.Net, CareDx, CTI BioPharma, EUSA Pharma, Inc., Novartis Pharmaceuticals Corp, Pacylex, PharmaEssentia; Speaker/Preceptorship: AbbVie, Aplastic Anemia & MDS International Foundation, Curio Science LLC, Dava Oncology, Imedex, Magdalen Medical Publishing, Medscape, Neopharm, PeerView Institute for Medical Education, Physician Education Resource (PER), Physicians Education Resource (PER), Postgraduate Institute for Medicine, Stemline Therapeutics, Inc. F.M.-B. consults for AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, Daiichi Sankyo Co. Ltd., DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, F. Hoffman La Roche Ltd., GT Apeiron, Genentech Inc., Harbinger Health, IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Protai Bio Ltd, Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor and Zymeworks; serves on the advisory committee for Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Sanofi, Silverback Therapeutics, Spectrum Pharmaceuticals and Zentalis; and has received honoraria from Chugai Biopharmaceuticals; leads clinical trials that are funded or sponsored by Aileron Therapeutics, Inc., AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences, Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc. and Taiho Pharmaceutical Co. P.B. recieves research funding from Incyte, BMS, CTI BioPharma, Constellation (now Morphosys), Kartos, Blueprint Medicines, Cogent Biosciences, Ionis, Pfizer, Astellas, NS Pharma and Promedior, and honoraria from Incyte, BMS, CTI BioPharma, Sierra Oncology (now GSK), Blueprint Medicines, Cogent Biosciences, Abbvie, Karyopharm, Pharma Essentia, Novartis, Constellation (now Morphosys) and Kartos. A.M.T. is funded by OBI Pharma, Agenus, Parker Institute for Cancer Immunotherapy, Tvardi Therapeutics, Tempus, IMMATICS; Consulting or Advisory Roles: Vincerx, Diaccurate, BrYet, NEX-I, Macrogenics and BioEclipse. J.R. serves on the advisory board of Peptomyc, Kelun Pharmaceuticals/Klus Pharma, Ellipses Pharma, Molecular Partners and IONCTURA; receives research funding from Blueprint Medicines, Black Diamond Therapeutics, Merck Sharp & Dohme, Hummingbird, Yingli, Vall d’Hebron Institute of Oncology/Cancer Core Europe; receives clinical research support from Novartis, Spectrum Pharmaceuticals, Symphogen, BioAlta, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GalxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bycicle Therapeutics, Merus, Curis, Bayer, AadiBioscience, Nuvation, ForeBio, BioMed Valley Discoveries, Loxo Oncology, Hutchinson MediPharma, Cellestia, Deciphera, Ideaya, Amgen, Tango Therapeutics and Mirati Linnaeus Therapeutics; and receives travel support from the European Society for Medical Oncology. IACS-010759 was developed by scientists at MD Anderson. If this drug becomes FDA approved and commercially available, MD Anderson will profit from its sale. The remaining authors declare no competing interests.